Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats.
We examined the effects of FK506, an immunosuppressive agent, on the genesis of water immersion stress-induced gastric lesions in rats. Using high-performance liquid chromatography, four kinds of prostaglandins, ie, 6-keto-prostaglandin F1 alpha, prostaglandin F2 alpha, prostaglandin E2, and prostaglandin D2, were detected, and no leukotrienes were detected in gastric mucosa in rats without stress. After 6 hr of stress, gastric lesions developed with decreases in all prostaglandin contents, and the emergence of peptide leukotrienes was observed. Intramuscular administration of FK506 (0.1, 0.25, 0.5, 1.0, and 2.0 mg/kg) reduced lesion index dose-dependently. Administration of FK506 at doses over 0.25 mg/kg decreased all prostaglandin contents, but did not affect the increase in leukotriene contents. Pretreatment with famotidine or omeprazole reduced lesion index, and the protective effects were equivalent to those of 1.0 mg/kg of FK506, although FK506 did not affect gastric secretion during water-immersion stress. Water-immersion stress did not change the activities of xanthine oxidase in either stomach or serum. Polyoxyethylene-modified superoxide dismutase did not prevent gastric lesions. Water-immersion stress significantly increased myeloperoxidase activity in gastric mucosa, and FK506 reduced the increase in myeloperoxidase activity induced by stress. From our results, other factors besides gastric acid secretion and tissue eicosanoid contents, such as chemoattractant factor, might also be involved in the genesis of water-immersion stress-induced gastric lesions in rats.
Hamajima
E
E
Department of Internal Medicine II, Faculty of Medicine, University of Nagoya, Japan.
Sugiyama
S
S
Hoshino
H
H
Goto
H
H
Tsukamoto
Y
Y
Ozawa
T
T
D000818:Animals; D015738:Famotidine / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D007101:Immersion; D015289:Leukotrienes / Q000378:metabolism; D008297:Male; D009853:Omeprazole / Q000494:pharmacology; D009195:Peroxidase / Q000378:metabolism; D011092:Polyethylene Glycols / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000209:etiology / Q000517:prevention & control*; D013312:Stress, Physiological / Q000150:complications*; D013482:Superoxide Dismutase / Q000494:pharmacology; D016559:Tacrolimus / Q000627:therapeutic use*; D014969:Xanthine Oxidase / Q000378:metabolism
D015289:Leukotrienes; D011453:Prostaglandins; D011092:Polyethylene Glycols; D015738:Famotidine; D009195:Peroxidase; D013482:Superoxide Dismutase; C077064:polyoxyethylene-superoxide dismutase; D014969:Xanthine Oxidase; D009853:Omeprazole; D016559:Tacrolimus